The global microRNA market size is expected to reach USD 3.51 billion by 2028 according to a new study by Polaris Market Research. The report “microRNA Market Share, Size, Trends, Industry Analysis Report, By Product (Instruments, Consumables); By Services (Service Type, Specimen); By Application (Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease); By End-Use; By Regions; Segment Forecast, 2021 – 2028” gives a detailed insight into current market dynamics and provides analysis on future market growth.
The rising adoption of microRNA as a biomarker is also driving the market. These biomarkers are particularly important in genome-wide population studies, data-driven methods, as they have the ability to demonstrate high robustness and reproducibility, as compared to traditional procedures. Hence, such molecules serve as a promising drug candidate to develop biomarkers. Moreover, growing interest in liquid-based biopsies has further led to its increased importance in biomarker discovery and further development.
Continuous rise in research activities has also explored the potential of microRNA biomarkers across prognosis, therapeutics, and diagnosis to favor the market expansion in near future. In this direction, in January 2020, research scholars have explored the presence of microRNA in the peripheral blood vessel as a biomarker to diagnose bipolar II disorder using NGS. These microRNAs could serve as a possible non-invasive solution to diagnose any indication of neurodegenerative disorders.
The cardiovascular segment is projected to witness a lucrative market growth rate over the assessment period. This is primarily due to the introduction of novel biomarkers for early diagnosis of heart-related ailments, and significant investments in the sector.
microRNAs are presumed to be an attractive option for cardiovascular therapeutics due to their several benefits such as tissue-specific expressions, secretion of body fluids, and stability. Moreover, many studies gave also pointed to the role of microRNAs in the regulation of lipoprotein metabolism, hypertension, blood pressure, and even progression of adjacent co-morbidities.
Asia Pacific market is projected to witness a lucrative growth rate over the microRNA study period. The growth in the region is primarily due to advancements in genomics and proteomics in genomic studies and the rapid adoption of new tools supporting research goals.
For instance, in March 2021, researchers based in Chinese universities have identified blood microRNA as a potential biomarker for hepatic sinusoidal obstruction syndrome via microarray-based profiling. In addition, a market study has also paved several computational tools to predict the relation between miRNA and its target microRNA.
Market participants operating in the microRNA industry include Merck KgaA, Thermo Fisher, BioGenex, New England Biolabs, Horizon Discovery, GeneCopoeia, Quantabio, NanoString, SeqMatic LLC, Sistemic Scotland Limited, Synlogic, QIAGEN, Miltenyi Biotec, Biodynamics Laboratory Inc., OriGene Technologies.
Polaris Market research has segmented the microRNAs market report on the basis of product, services, application, end-use and region:
microRNA, Product Outlook (Revenue – USD Million, 2016 – 2028)
microRNA, Services Outlook (Revenue – USD Million, 2016 – 2028)
- Service Type
- Isolation & Purification
- miRNA cDNA Synthesis
- Profiling, Localization, & Quantification
- Functional Analysis
- Whole Blood
- Fresh Frozen Tissue
microRNA, Application Outlook (Revenue – USD Million, 2016 – 2028)
- Infectious Diseases
- Immunological Disorder
- Cardiovascular Disease
- Neurological Disease
microRNA, End Use Outlook (Revenue – USD Million, 2016 – 2028)
- Biotechnology & Pharmaceutical Companies
- Academic & Government Research Institutes
Ask Our Expert for customization and feasibility @ https://www.polarismarketresearch.com/industry-analysis/microrna-market/request-for-customization